These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1624 related articles for article (PubMed ID: 33772933)

  • 1. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
    Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
    Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
    Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
    Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
    Zequn Z; Yujia W; Dingding Q; Jiangfang L
    Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
    Hsia BC; Greige N; Quiroz JA; Khokhar AS; Daily J; Di Biase L; Ferrick KJ; Fisher JD; Krumerman A
    J Interv Card Electrophysiol; 2020 Nov; 59(2):337-345. PubMed ID: 32654098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
    O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
    JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic.
    Rubin GA; Desai AD; Chai Z; Wang A; Chen Q; Wang AS; Kemal C; Baksh H; Biviano A; Dizon JM; Yarmohammadi H; Ehlert F; Saluja D; Rubin DA; Morrow JP; Avula UMR; Berman JP; Kushnir A; Abrams MP; Hennessey JA; Elias P; Poterucha TJ; Uriel N; Kubin CJ; LaSota E; Zucker J; Sobieszczyk ME; Schwartz A; Garan H; Waase MP; Wan EY
    JAMA Netw Open; 2021 Apr; 4(4):e216842. PubMed ID: 33890991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
    Baralić K; Jorgovanović D; Živančević K; Antonijević Miljaković E; Antonijević B; Buha Djordjevic A; Ćurčić M; Đukić-Ćosić D
    Toxicol Appl Pharmacol; 2020 Nov; 406():115237. PubMed ID: 32920000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
    Eftekhar SP; Kazemi S; Barary M; Javanian M; Ebrahimpour S; Ziaei N
    Cardiovasc Ther; 2021; 2021():6683098. PubMed ID: 33688374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
    Echarte-Morales J; Minguito-Carazo C; Del Castillo-García S; Borrego-Rodríguez J; Rodríguez-Santamarta M; Sánchez-Muñoz E; Bergel-García R; González-Maniega C; Prieto-González S; Menéndez-Suarez P; Tundidor-Sanz E; Benito-González T; Fernández-Vázquez F
    J Electrocardiol; 2021; 64():30-35. PubMed ID: 33307378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
    Carron J; Sharif Z; Hussein H; Kennedy M; McAdam B; Sheahan R
    Ir J Med Sci; 2021 Feb; 190(1):403-409. PubMed ID: 32627127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
    Sarayani A; Cicali B; Henriksen CH; Brown JD
    Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
    Moschini L; Loffi M; Regazzoni V; Di Tano G; Gherbesi E; Danzi GB
    Heart Vessels; 2021 Jan; 36(1):115-120. PubMed ID: 32676695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
    Chorin E; Wadhwani L; Magnani S; Dai M; Shulman E; Nadeau-Routhier C; Knotts R; Bar-Cohen R; Kogan E; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Stefano C; Chinitz LA; Jankelson L
    Heart Rhythm; 2020 Sep; 17(9):1425-1433. PubMed ID: 32407884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
    Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
    Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
    Ding J; Liu W; Guan H; Feng Y; Bao Y; Li H; Wang X; Zhou Z; Chen Z
    Medicine (Baltimore); 2021 Jul; 100(28):e26538. PubMed ID: 34260531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mercuro NJ; Yen CF; Shim DJ; Maher TR; McCoy CM; Zimetbaum PJ; Gold HS
    JAMA Cardiol; 2020 Sep; 5(9):1036-1041. PubMed ID: 32936252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine.
    Andy Ko TY; Chen LS; Pang IX; Ling HS; Wong TC; Sia Tonnii LL; Koh KT
    Med J Malaysia; 2021 Mar; 76(2):125-130. PubMed ID: 33742617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.
    Saleh M; Gabriels J; Chang D; Fishbein J; Qiu M; Mountantonakis SE; Epstein LM;
    Circ Arrhythm Electrophysiol; 2020 Nov; 13(11):e008937. PubMed ID: 33003964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.
    Vouri SM; Thai TN; Winterstein AG
    Res Social Adm Pharm; 2021 Jan; 17(1):2012-2017. PubMed ID: 32409150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 82.